RRx-001, currently undergoing phase III clinical trials, has a reasonably good safety profile and is a promising therapeutic candidate for stroke.401 Meanwhile, inhibition of Janus kinase can ameliorate ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition.402 More drugs, such as lonidamine, edaravone dexborneol, thiolutin, and β-1, 3-galactosyltransferase-2, may inhibit NLRP3 assembly. The gene discussed is NLRP3; the disease is ischemic stroke.